Daniel P. Cahn

Array ( [id] => 20583288 [patent_doc_number] => 20260068878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-12 [patent_title] => COMPOSITION [patent_app_type] => utility [patent_app_number] => 19/319256 [patent_app_country] => US [patent_app_date] => 2025-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5875 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19319256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20279292 [patent_doc_number] => 20250304534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-02 [patent_title] => Preparation and Application of Deuterated 4-Phenyl-4-Piperidinols [patent_app_type] => utility [patent_app_number] => 19/238297 [patent_app_country] => US [patent_app_date] => 2025-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25518 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19238297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20240881 [patent_doc_number] => 12421188 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Heterocyclic compound and use thereof [patent_app_type] => utility [patent_app_number] => 19/079172 [patent_app_country] => US [patent_app_date] => 2025-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47022 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19079172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227139 [patent_doc_number] => 12415782 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Heterocyclic compound and use thereof [patent_app_type] => utility [patent_app_number] => 19/079211 [patent_app_country] => US [patent_app_date] => 2025-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46928 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19079211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20678071 [patent_doc_number] => 20260116883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-30 [patent_title] => CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1- METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING [patent_app_type] => utility [patent_app_number] => 18/800215 [patent_app_country] => US [patent_app_date] => 2024-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18800215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586315 [patent_doc_number] => 20240383872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => NOVEL PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF CANNABINOID RECEPTOR 2 [patent_app_type] => utility [patent_app_number] => 18/785279 [patent_app_country] => US [patent_app_date] => 2024-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18785279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658439 [patent_doc_number] => 20240425504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => IMIDAZOPYRIDINONE COMPOUND [patent_app_type] => utility [patent_app_number] => 18/782102 [patent_app_country] => US [patent_app_date] => 2024-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27912 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18782102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554774 [patent_doc_number] => 20240366566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => USE OF CARBAMATE COMPOUND FOR PREVENTION, ALLEVIATION OR TREATMENT OF STATUS EPILEPTICUS [patent_app_type] => utility [patent_app_number] => 18/777900 [patent_app_country] => US [patent_app_date] => 2024-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18777900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556274 [patent_doc_number] => 20240368066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES [patent_app_type] => utility [patent_app_number] => 18/764540 [patent_app_country] => US [patent_app_date] => 2024-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 461 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846679 [patent_doc_number] => 20250092030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A [patent_app_type] => utility [patent_app_number] => 18/763690 [patent_app_country] => US [patent_app_date] => 2024-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18763690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19682290 [patent_doc_number] => 20250000835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => SYNERGIES OF 1- BETA-CARYOPHYLLENE, CANNABIDIOL AND TRIBUTYRIN; 2- RETINYL PALMITATE, BETA-CARYOPHYLLENE AND CANNABIDIOL; 3- RETINYL PALMITATE AND BETA-CARYOPHYLLENE IN CONTROLING INFLAMMATION, METABOLIC HEALTH, INSULIN SENSITIVITY/ GLYCEMIC - GLUCOSE UPTAKE & MANAGEMENT, AND FATTY LIVER/ NAFLD [patent_app_type] => utility [patent_app_number] => 18/763849 [patent_app_country] => US [patent_app_date] => 2024-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18763849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20771459 [patent_doc_number] => 12655118 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-16 [patent_title] => CGAS antagonist compounds [patent_app_type] => utility [patent_app_number] => 18/759546 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39704 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 593 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18759546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692776 [patent_doc_number] => 20250011321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => Nonlinear Optical Chromophores with Indolizine Donor Groups [patent_app_type] => utility [patent_app_number] => 18/756051 [patent_app_country] => US [patent_app_date] => 2024-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18756051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745554 [patent_doc_number] => 20250034119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => COMPOUNDS, COMPOSITIONS, AND METHODS [patent_app_type] => utility [patent_app_number] => 18/744133 [patent_app_country] => US [patent_app_date] => 2024-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18744133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19629663 [patent_doc_number] => 20240408112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => METHOD FOR PREVENTING OR TREATING PULMONARY ARTERIAL HYPERTENSION BY USING 7-DEHYDROCHOLESTEROLS OR SALTS, OXIDES, METABOLITES, OR DERIVATIVES THEREOF [patent_app_type] => utility [patent_app_number] => 18/734287 [patent_app_country] => US [patent_app_date] => 2024-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20535708 [patent_doc_number] => 12552772 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD [patent_app_type] => utility [patent_app_number] => 18/734899 [patent_app_country] => US [patent_app_date] => 2024-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 131654 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20385408 [patent_doc_number] => 12485117 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-02 [patent_title] => Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin [patent_app_type] => utility [patent_app_number] => 18/667468 [patent_app_country] => US [patent_app_date] => 2024-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 46 [patent_no_of_words] => 13410 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18667468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372380 [patent_doc_number] => 12479802 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Phenyl-n-quinoline derivatives for treating a RNA virus infection [patent_app_type] => utility [patent_app_number] => 18/660578 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20264 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18660578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430829 [patent_doc_number] => 20240299327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders [patent_app_type] => utility [patent_app_number] => 18/659715 [patent_app_country] => US [patent_app_date] => 2024-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18659715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418403 [patent_doc_number] => 20240294526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => FUSED TRI-CYCLIC COMPOUND AS A PDE3/PDE4 DUAL INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/641912 [patent_app_country] => US [patent_app_date] => 2024-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17764 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18641912 [rel_patent_id] =>[rel_patent_doc_number] =>)